AMOT

Across TCGA pan-cancer cohorts, AMOT mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated AMOT data layer compared with 16 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher AMOT mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated AMOT expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, LUAD, and PDAC are the cancer types where AMOT mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Quartile	All	0.958	0.659	.003	25	view →
LUAD	DFS	Quartile	All	0.737	0.964	.011	7	view →
PDAC	OS	Tertile	II,III,IV	1.000	0.729	.004	5	view →
LSCC	OS	Median	All	0.890	0.717	.025	2	view →
GBM	OS	Median	All	0.781	0.927	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

AMOT–CCRCC (OS)

Open the CCRCC breakdown →